Oramed Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin c Read MoreOramed Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Oramed Pharmaceuticals Inc
Score